CRDL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	567 410
Average Volume	396 611
Market Cap	115.25M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $0 ) 2024-05-17
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.10
ATR14	$0.0140 (0.80%)

Volume Correlation

Long: -0.01 (neutral)

Short: 0.95 (very strong)

Signal:(57.979) Expect same movement, but be aware

Cardiol Therapeutics Inc. Correlation

10 Most Positive Correlations
LCAA	0.926
MOR	0.925
AMZN	0.916
CACG	0.913
CGNT	0.91
EWZS	0.907
ONEQ	0.905
MDB	0.902
DFH	0.901
BUFF	0.901

10 Most Negative Correlations
OBNK	-0.891
BLTE	-0.875
PAYS	-0.869
JRSH	-0.862
PLXP	-0.86
EDAP	-0.859
PHCF	-0.857
VBFC	-0.856
SOPA	-0.849
LBPS	-0.846

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cardiol Therapeutics Inc. Correlation - Currency/Commodity

0.08
( neutral )

0.40
( neutral )

0.00
( neutral )

-0.83
( strong negative )

-0.68
( moderate negative )

0.12
( neutral )

Cardiol Therapeutics Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$-219 908 (0.00 %)
EPS:	$-0.490

Q3	2023
Revenue:	$0
Gross Profit:	$-64 893.00 (0.00 %)
EPS:	$-0.0920

Q2	2023
Revenue:	$0
Gross Profit:	$-58 496.00 (0.00 %)
EPS:	$-0.120

Q1	2023
Revenue:	$0
Gross Profit:	$-58 205.00 (0.00 %)
EPS:	$-0.110

Financial Reports:

No articles found.

Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.